Table 3. Model-Based Estimated Treatment Effects.
| Outcome | Change at 6 mo | Persistence Between 6 and 9 mo | ||
|---|---|---|---|---|
| Treatment Effect, OR (95% CI) | P Value | Difference, OR (95% CI) | P Value | |
| Primary outcomes | ||||
| Proportion of children screened appropriately for autism | 1.29 (0.46 to 3.57) | .63 | 0.72 (0.42 to 1.23) | .23 |
| Proportion of comorbid medical problems appropriately addressed in children with autism | 0.80 (0.35 to 1.82) | .59 | 1.40 (0.82 to 2.40) | .22 |
| Secondary outcomes | ||||
| Proportion of children screened appropriately for general development | 0.80 (0.13 to 5.04) | .81 | 1.18 (0.44 to 3.16) | .73 |
| Proportion of comorbid medical conditions identified for each child with autisma | 1.16 (0.69 to 1.94) | .57 | 1.11 (0.82 to 1.50) | .49 |
| Knowledge Score, Δ (95% CI) | 8.54 (4.09 to 12.98) | <.001 | 0.62 (−2.24 to 3.48) | .67 |
| Self-efficacy Total Score, Δ (95% CI)b | 29 (25 to 32) | <.001 | 1 (−1 to 4) | .29 |
| Total perceived barriers to care (of 10 possible), Δ (95% CI) | −2.20 (−2.74 to −1.67) | <.001 | 0.02 (−0.37 to 0.41) | .92 |
Abbreviation: OR, odds ratio.
a
Among 4 prespecified conditions (anxiety, behavioral problems, constipation, and sleep disorders).
b
Ranging from 0 to 100, with higher scores meaning higher perceived self-efficacy.